Mark J. Holdbrook - 17 Mar 2023 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
V.P., Clinical Affairs
Signature
/s/ Leonard M. Greenstein, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
17 Mar 2023
Net transactions value
-$4,993
Form type
4
Filing time
21 Mar 2023, 19:06:38 UTC
Previous filing
17 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Sale $2,497 -188 -5.3% $13.28 3,389 17 Mar 2023 Direct F1
transaction TARS Common Stock Sale $2,497 -198 -5.8% $12.61 3,191 20 Mar 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Mark J. Holdbrook is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.